Stifel Financial Corp increased its stake in Genmab A/S (NASDAQ:GMAB) by 1.7% during the fourth quarter, HoldingsChannel reports. The firm owned 96,843 shares of the company’s stock after acquiring an additional 1,654 shares during the period. Stifel Financial Corp’s holdings in Genmab A/S were worth $2,212,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors have also recently bought and sold shares of the stock. Navellier & Associates Inc bought a new position in Genmab A/S during the fourth quarter valued at $646,000. Advisor Group Inc. lifted its position in shares of Genmab A/S by 81.3% during the 4th quarter. Advisor Group Inc. now owns 4,249 shares of the company’s stock valued at $94,000 after buying an additional 1,906 shares during the last quarter. Chevy Chase Trust Holdings Inc. bought a new position in shares of Genmab A/S during the 4th quarter worth $38,000. Raymond James & Associates grew its stake in shares of Genmab A/S by 7.4% during the 4th quarter. Raymond James & Associates now owns 119,784 shares of the company’s stock worth $2,675,000 after acquiring an additional 8,233 shares during the period. Finally, Citigroup Inc. grew its stake in shares of Genmab A/S by 479.7% during the 4th quarter. Citigroup Inc. now owns 14,399 shares of the company’s stock worth $320,000 after acquiring an additional 11,915 shares during the period. Institutional investors and hedge funds own 18.38% of the company’s stock.
Shares of NASDAQ GMAB traded up $0.16 during mid-day trading on Thursday, hitting $20.17. The company had a trading volume of 5,437 shares, compared to its average volume of 521,875. The company has a current ratio of 14.88, a quick ratio of 18.72 and a debt-to-equity ratio of 0.01. Genmab A/S has a 1 year low of $16.24 and a 1 year high of $25.42. The company has a market capitalization of $2.51 billion and a price-to-earnings ratio of 10.16. The stock’s 50-day moving average price is $22.48 and its 200-day moving average price is $21.95.
A number of equities research analysts recently issued reports on GMAB shares. Zacks Investment Research upgraded Genmab A/S from a “sell” rating to a “hold” rating in a research note on Thursday, February 27th. SunTrust Banks initiated coverage on shares of Genmab A/S in a research report on Monday, January 13th. They set a “buy” rating for the company. Morgan Stanley lifted their target price on shares of Genmab A/S from $30.00 to $31.00 and gave the stock an “overweight” rating in a research note on Thursday, February 20th. ValuEngine raised shares of Genmab A/S from a “sell” rating to a “hold” rating in a research report on Tuesday, December 3rd. Finally, Deutsche Bank downgraded shares of Genmab A/S from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $26.50.
Genmab A/S Profile
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL).
Further Reading: What is a dividend reinvestment plan?
Want to see what other hedge funds are holding GMAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genmab A/S (NASDAQ:GMAB).
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.